Nucleic acid construct and method of preparing nanoparticle using the same

Patent metadata

Field	Value
Publication number	US-9334301-B2
Application number	US-201313771374-A
Country	US
Kind code	B2
Filing date	Feb 20, 2013
Priority date	May 21, 2012
Publication date	May 10, 2016
Grant date	May 10, 2016

Abstract

A nucleic acid construct, a method of preparing a nanoparticle by using the nucleic acid construct, and a nanoparticle and nanoparticle complex prepared using the method. Various types of metal nanoparticles may be efficiently prepared using the template for preparing a nanoparticle and the nanoparticle prepared using the template.

First claim

What is claimed is:

1. A nanoparticle comprising a metal ion and a nucleic acid construct,
wherein the nucleic acid construct comprises at least two single-stranded nucleic acids, each of the at least two single-stranded nucleic acids comprising at least ten nucleotides arranged in at least two adjacent segments, wherein each segment of one single-stranded nucleic acid is complementary to a segment of another of the single-stranded nucleic acids, and wherein each pair of complementary segments is hybridized so that the nucleic acid construct comprises a plurality of double-stranded segments; and
wherein the metal ion is bound directly to a phosphate backbone of the nucleic acid construct to form a metal layer, and the metal ion is an ion of a metal selected from the group consisting of gold, copper, platinum, palladium, and combinations thereof,
wherein the nucleic acid construct comprises at least one cross-linking or intercalating agent between two nucleic acid strands where the segments are substantially complementarily bound to each other.

2. The nanoparticle of claim 1 , wherein the nucleic acid construct comprises 2 to 10 single-stranded nucleic acids.

3. The nanoparticle of claim 1 , wherein each of the at least two single-stranded nucleic acids comprises 2 to 5 segments.

4. The nanoparticle of claim 1 , wherein the nucleic acid construct comprises X-shaped, Y-shaped, liner, or a dumbbell-shaped double stranded segments.

5. A nanoparticle complex comprising at least two of the nanoparticles of claim 1 , wherein an end of one of the at least two of the nanoparticles is bound to an end of the other thereof.

6. The nanoparticle complex of claim 5 , wherein the nucleic acids are selected from the group consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), peptide nucleic acid (PNA), locked nucleic acid (LNA), and analogs thereof.

7. A method of preparing a nanoparticle, the method comprising:
mixing at least two single-stranded nucleic acids each comprising at least two adjacent segments, wherein each segment of one single-stranded nucleic acid is complementary to a segment of another single-stranded nucleic acid, to give a nucleic acid construct in which the complementary segments are hybridized, and wherein the resulting nucleic acid construct comprises a plurality of double-stranded segments;
adding an intercalator to a resultant of the hybridization and allowing the intercalator to be intercalated into the double-stranded segments;
contacting the nucleic acid construct with a metal ion, wherein a the metal ion is an ion of a metal selected from the group consisting of gold, copper, platinum, palladium, and combinations thereof; and
subjecting the metal ion to reduction to prepare a nanoparticle comprising the metal ion and the nucleic acid construct,
wherein the metal ion is bound directly to a phosphate backbone of the nucleic acid construct to form a metal layer, and the metal ion is an ion of a metal selected from the group consisting of gold, copper, platinum, palladium, and combinations thereof,
wherein the nucleic acid construct comprises at least one cross-linking or intercalating agent between two nucleic acid strands where segments are substantially complementarily bound to each other.

8. The method of claim 7 , wherein the intercalator is selected from the group consisting of psoralen, ethidium bromide, proflavine, daunomycin, doxorubicin, thalidomide, YOYO-1, TOTO-1, YOYO-3, TOTO-3, POPO-1, BOBO-1, POPO-3, BOBO-3, LOLO-1, JOJO-1, cyanine dimers, YO-PRO-1, TO-PRO-1, YO-PRO-3, TO-PRO-3, TO-PRO-5, PO-PRO-1, BO-PRO-1, PO-PRO-3, BO-PRO-3, LO-PRO-1, JO-PRO-1, cyanine monomers, ethidium homodimer-1, ethidium homodimer-2, ethidium derivatives, acridine, acridine orange, acridine derivatives, ethidium-acridine heterodimer, ethidium monoazide, propidium iodide, SYTO dyes, SYBR Green 1, SYBR dyes, Pico Green, SYTOX dyes, and 7-aminoactinomycin D.

9. The method of claim 7 , wherein the nucleic acids are selected from the group consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), peptide nucleic acid (PNA), locked nucleic acid (LNA), and analogs thereof.

10. The method of claim 7 , wherein the nucleic acid construct comprises 2 to 10 single-stranded nucleic acids.

11. The method of claim 7 , wherein each of the at least two single-stranded nucleic acids comprises 2 to 5 segments.

12. The nanoparticle of claim 1 , wherein the nucleic acid construct comprises three single-stranded nucleic acids, and wherein the three single-stranded nucleic acids are SEQ ID NO: 1, 2, and 3.

13. The nanoparticle of claim 7 , wherein three single-stranded nucleic acids are mixed, and the three single-stranded nucleic acids are SEQ ID NO: 1, 2, and 3.

14. The nanoparticle of claim 1 , wherein the cross-linking or intercalating agent is selected from the group consisting of psoralen, ethidium bromide, proflavine, daunomycin, doxorubicin, thalidomide, YOYO-1, TOTO-1, YOYO-3, TOTO-3, POPO-1, BOBO-1, POPO-3, BOBO-3, LOLO-1, JOJO-1, cyanine dimers, YO-PRO-1, TO-PRO-1, YO-PRO-3, TO-PRO-3, TO-PRO-5, PO-PRO-1, BO-PRO-1, PO-PRO-3, BO-PRO-3, LO-PRO-1, JO-PRO-1, cyanine monomers, ethidium homodimer-1, ethidium homodimer-2, ethidium derivatives, acridine, acridine orange, acridine derivatives, ethidium-acridine heterodimer, ethidium monoazide, propidium iodide, SYTO dyes, SYBR Green 1, SYBR dyes, Pico Green, SYTOX dyes, and 7-aminoactinomycin D.

Assignees

• Samsung Electronics Co Ltd

Inventors

• Park No-Kyoung

Classifications

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• C07H23/00 Primary

  Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12 (esters with inorganic acids C07H11/00) · CPC title

• C07H21/00 Primary

  Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids · CPC title

• B82B1/00

  Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units · CPC title

• B82B3/00 Primary

  Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units · CPC title